Answers are grounded in this paper and cite their sources.
A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol. We investigated the patient's serum for all frequent polymorphisms in cytochrome P450 2D6, assuming him to be a poor neuroleptic metabolizer. We will also discuss other potential mechanisms inducing this disturbance and its differential diagnoses.
No takes yet. Share an insight, caveat, or question.
Neu et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: